In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN – Research Report), with a price target of $6.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Longeveron’s lead investigational product, Laromestrocel (Lomecel-B). The completion of enrollment in the pivotal Phase 2b ELPIS II study for hypoplastic left heart syndrome (HLHS) is a significant milestone. This study is expected to provide crucial data on the efficacy of Laromestrocel, with the primary endpoint being the change in right ventricular ejection fraction, a critical measure for clinical outcomes in HLHS.
Furthermore, the FDA’s focus on facilitating approvals for rare pediatric diseases, coupled with positive survival data from earlier studies, strengthens the potential for regulatory success. The financial support from grant funding also alleviates some of the study’s expenses, making the financial outlook more favorable. Additionally, Longeveron’s strategic preparations for commercialization and the manageable market size for HLHS contribute to the positive recommendation, alongside a calculated valuation model that supports a 12-month price target of $6.00.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $10.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.